io1013S-ioGlutamatergic-Neurons-PRKN-R275W-heterozygous-ICC-MAP2 compressed

cat no | io1013

ioGlutamatergic Neurons
PRKN R275W/WT

Human iPSC-derived Parkinson's disease model

ioGlutamatergic Neurons PRKN R275W/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a heterozygous R275W mutation in Parkinson’s disease.

 

Request a quote >

 

Place your order

Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.

per vial

Add to basket

Click here for bulk request

Benchtop benefits

comparison_0

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of heterozygous expression of mutant Parkin protein on disease.

scalable_0

Scalable

With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

quick_0

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Technical data

Highly characterised and defined

ioGlutamatergic Neurons PRKN R275W/WT express neuron-specific markers comparably to the isogenic control

ICC showing glutamatergic neurons with heterozygous R275W mutation in the PRKN gene expressing pan-neuronal markers in an equivalent manner to an isogenic control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PRKN R275W/WT compared to the isogenic control. 100X magnification.

ioGlutamatergic Neurons PRKN R275W/WT form structural neuronal networks by day 11

Incucyte imaging of ioGlutamatergic Neurons PRKN R275W/WT over 11 days, showing the cells form structural neuronal networks

ioGlutamatergic Neurons PRKN R275W/WT mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.

ioGlutamatergic Neurons PRKN R275W/WT demonstrate gene expression of neuronal and glutamatergic-specific markers following reprogramming

RT-qPCR of ioGlutamatergic Neurons PRKN R275W hom showing expression of pan neuronal and glutamatergic markers
Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/WT and the isogenic control (WT) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.
Disease-related PRKN is expressed in ioGlutamatergic Neurons PRKN R275W/WT following reprogramming
RT-qPCR of ioGlutamatergic Neurons PRKN R275W/WT showing expression of the PRKN gene
Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/WT and the isogenic control (WT) express the PRKN gene encoding the Parkin protein. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.

Cells arrive ready to plate

ioGlutamatergic Neurons PRKN R275W/WT arrive ready to plate and are ready for experimentation in 11 days

ioGlutamatergic Neurons PRKN R275W/WT are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 4 days (Phase 1), and Maintenance (Phase 2) during which the ioGlutamatergic Neurons PRKN R275W/WT mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Industry leading seeding density

ioGlut-MAPT-P301S-P301S-well_plate-1

ioGlutamatergic Neurons PRKN R275W/WT cells are compatible with plates ranging from 6 to 384 wells.
The recommended seeding density is 30,000 cells/cm2, compared to up to 500,000 cells/cm2 for other similar products on the market.
This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality. Resulting in more experimental conditions, more repeats, and more confidence in the data.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate. 

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 106 viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Heterozygous R275W missense mutation in the PRKN gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

Product resources

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease Poster
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Smith et al. 
bit.bio
2024
Downlaod
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™ Case study
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™

Professor Deepak Srivastava

Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders

King’s College London 

Download
Running Large-Scale CRISPR Screens in Human Neurons Webinar
Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency Talk
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency

Innovation showcase talk at ISSCR

Marius Wernig MD, PhD | Stanford 

Mark Kotter, MD, PhD | bit.bio

Watch now
Modelling neurodegeneration: Human isogenic system to study FTD & ALS Poster
Modelling neurodegeneration: Human isogenic system to study FTD & ALS

Oosterveen, et al

bit.bio & Charles River Laboratories

2023

Download
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now

Addressing current challenges of in vitro cell models 

Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.

bit-bio_Addressing the challenges of cell models_Blog_Image1200x755

Related products

ioGlutamatergic Neurons PRKN R275W/R275W™ ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/R275W™ cat no. io1020
Order now
ioGlutamatergic Neurons™ ioWild Type Cells
ioGlutamatergic Neurons™ cat no. io1001
Order now
CRISPR-Ready ioGlutamatergic Neurons™ ioCRISPR-Ready Cells
CRISPR-Ready ioGlutamatergic Neurons™ cat no. ioEA1090
Order now
ioGlutamatergic Neurons GBA null/WT™ ioDisease Model Cells
ioGlutamatergic Neurons GBA null/WT™ cat no. io1007
Order now
ioGlutamatergic Neurons HTT 50CAG/WT™ ioDisease Model Cells
ioGlutamatergic Neurons HTT 50CAG/WT™ cat no. ioEA1004
Order now
ioGlutamatergic Neurons MAPT N279K/WT™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/WT™ cat no. io1009
Order now
ioGlutamatergic Neurons MAPT P301S/WT™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT P301S/WT™ cat no. io1015
Order now
ioGlutamatergic Neurons TDP‑43 M337V/WT™ ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/WT™ cat no. ioEA1006
Order now
ioGlutamatergic Neurons MAPT N279K/N279K™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/N279K™ cat no. io1014
Order now
ioGlutamatergic Neurons MAPT P301S/P301S™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT P301S/P301S™ cat no. io1018
Order now
ioGlutamatergic Neurons TDP‑43 M337V/M337V™ ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/M337V™ cat no. ioEA1005
Order now

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide-B

Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery
Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform that powers our ioCells